Kyndryl reports fiscal Q2 2027 revenue of $3.7B
Kyndryl reported revenues of $3.7 billion and a net income of $59 million for the fiscal second quarter of 2027, while reaffirming its financial outlook.
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Kyndryl reported revenues of $3.7 billion and a net income of $59 million for the fiscal second quarter of 2027, while reaffirming its financial outlook.
Dine Brands Global reported Q3 2026 net income of $4.5 million due to customer demand for Applebee's and IHOP value menus, highlighting successful operational execution.
Lifecore reported a third-quarter net loss of $40.1 million highlighting growing challenges despite securing new CDMO contracts.
Rapport Therapeutics reported positive Phase 2 trial results for RAP-219 in bipolar mania, and management expects to initiate two Phase 3 trials in 2H 2027.
Geron reported $60.1M net product revenue, up 10% QoQ, and reiterated a high-end revenue guidance of $240M. The company announced a gated commercial launch in European markets to e…
Datadog reported $1.20 billion in Q3 2026 revenue, up 35% year-over-year, despite GAAP operating margin dipping to roughly 6%. The company also launched Scout 1.0 to improve custom…
Viridian reported $24.7M in Lumvoa net product revenue with 100+ patients on therapy in Q3 2026. The company currently holds $955.2M in cash and announced the initiation of a phase…
Shoals Technologies Group reported Q3 2026 revenue of $195.3 million and raised its full-year outlook, driven by strong customer demand and operational improvements. The company re…
CDW reported strong third quarter financial results with robust growth in net sales and net income per diluted share to $6,754.5 million and $2.46, respectively. The company also a…
Nuvectis reports Q3 2026 financial results and details the in-licensing of two drugs, ciprocopan and NXP200, while awaiting FDA updates before year-end.
RXTHM reported Q3 2026 revenue of $23.9 million and adjusted EBITDA of $5.9 million. The company also amended a license agreement with Green Thumb Industries to raise the Señ…
Criteo reported lower quarterly revenue driven by headwinds but expanded Performance CTV and open AI partnerships. Media spend increased 9% year-over-year.
Seres Therapeutics reported Q3 2026 financial results and announced plans to submit a new study design for SER-155 to the FDA in Q1 2027, which aims to prevent immune checkpoint in…
Wayfair reported Q3 net revenue of $3.4 billion, with U.S. sales growing double digits. The company's adjusted EBITDA increased to $236 million, marking the strongest growth quarte…
The New York Times reported a 14.6% increase in digital-only subscription revenues driven by 420,000 net new subscribers and higher average revenue per user. The company also excee…
Cushman & Wakefield reported third quarter 2026 revenue of $2.81 billion and maintained its full year Adjusted EPS guidance range. The firm also noted $800 million in cumulative de…
Revenue and Adjusted EBITDA fell year-over-year due to commodity inflation and volume declines, though revenue grew from Q3 2025. Diluted EPS dropped despite productivity gains.
Advantage Solutions reported Q3 2026 revenues of $782 million and a net loss of $25.1 million, driven by weakness in Branded Services. The company announced restructuring actions t…
Bruker reported Q3 2026 revenue of $874.0 million, a 1.6% year-over-year increase, and non-GAAP diluted EPS of $0.56, reflecting significant margin expansion driven by improved cos…
PFGC posted strong Q1 fiscal 2027 earnings with $18.0 billion in net sales and $129.5 million in net income, driven by solid momentum in case volumes despite inflation.